Stephen Mitchener, PharmD, brings 15 years of pharmaceutical industry experience driving domestic and international commercialization, multidisciplinary partnering, business and operational development, and value creation.

Dr. Mitchener built a 15-year career at Novartis Pharmaceuticals, most recently as Head of U.S. Oncology Strategy, Partnering and Operations. In this Executive team role, he led all business development and collaborations for Novartis U.S. Oncology across academic, big data, pipeline, product and technology partnering initiatives. In addition, he had responsibility for Loss of Exclusivity (LoE), Companion Diagnostic (CDx) and Enterprise Operations for a $5 billion P&L.

Dr. Mitchener has also led both commercial evaluations for successful global product acquisitions and BD&L activities for multiple products. In his commercial roles, Dr. Mitchener helped lead and transition assets in immunology, infectious diseases, oncology and rare diseases from research through commercialization for the company.

Previously, Dr. Mitchener was the Business Franchise Head at Novartis Oncology for Australia & New Zealand, managing 13 products including 5 new launches. Dr. Mitchener was a Board Observer for COTA Healthcare, where he provided guidance on operations, strategy, and Series C financing on behalf of Novartis Oncology.

Dr. Mitchener received his Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill and conducted his Postdoctoral work at Rutgers University and Novartis Oncology.